Shanghai, China – On May 12, Fanpu Kong, Director of Center for Medical Device Evaluation of China Food and Drug Administration ("CFDA") and Lai Xu, Deputy Head of Shanghai Food and Drug Administration visited Shanghai MicroPort Medical (Group) Co., Ltd. ("MicroPort®"). MicroPort® Chairman and Chief Executive Officer Dr. Zhaohua Chang and Yimin Xu, Executive Vice President of Regulatory Affairs and Property Management received the team.
Director Kong and his team were shown around MicroPort® Self-Experience Center, Technology Corridor, Precision Tube Technology Center, Laser Precision Machining Center and Testing Center, and were briefed about the technology innovation, product clinical application, and future development plan of MicroPort®'s various business segments. They said they were impressed by MicroPort®'s innovative products.
In the following panel discussion, the two sides exchanged ideas regarding original equipment manufacturing, cross-provincial manufacturing site, flight check public notification, and detection resources allocation. Director Kong introduced the productive efforts CFDA made in optimizing the approval system and put forward his own opinion regarding the questions raised by enterprise. Director Kong said, this visit not only enhanced the mutual understanding between the CFDA and MicroPort®, but also helped to refine the reform of medical device approval systems and promote the development of China's medical device industry.